Comparing Gyre Therapeutics (NASDAQ:GYRE) & IGM Biosciences (NASDAQ:IGMS)

Gyre Therapeutics (NASDAQ:GYRE) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Gyre Therapeutics and IGM Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-84.57%	-118.43%	-71.97%
IGM Biosciences	-7,534.03%	-155.42%	-61.04%

Valuation & Earnings

This table compares Gyre Therapeutics and IGM Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$105.03 million	9.19	-$92.93 million	N/A	N/A
IGM Biosciences	$2.92 million	26.90	-$246.42 million	($3.64)	-0.36

Gyre Therapeutics has higher revenue and earnings than IGM Biosciences.

Analyst Recommendations

This is a summary of recent recommendations for Gyre Therapeutics and IGM Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	0	0	0	0	0.00
IGM Biosciences	1	9	0	0	1.90

IGM Biosciences has a consensus price target of $5.50, suggesting a potential upside of 316.67%. Given IGM Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe IGM Biosciences is more favorable than Gyre Therapeutics.

Institutional & Insider Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 57.0% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Gyre Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Summary

IGM Biosciences beats Gyre Therapeutics on 6 of the 11 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About IGM Biosciences

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.